0001104659-24-031908.txt : 20240307 0001104659-24-031908.hdr.sgml : 20240307 20240307161607 ACCESSION NUMBER: 0001104659-24-031908 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240307 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 24730328 BUSINESS ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 8-K 1 tm248235d1_8k.htm FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 7, 2024

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37759	38-3982704
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

485 Route 1 South

Building F, Suite 320

Iselin, New Jersey

08830

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (609) 619-3990

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		OTLK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

At the 2024 Annual Meeting of Stockholders (the “Annual Meeting”), the stockholders of Outlook Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 425,000,000 to 1,200,000,000 shares. The increase in the authorized number of shares of the Company’s common stock was effected pursuant to a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on March 7, 2024 and was effective as of such date. The foregoing description is qualified in its entirety by the Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07

Submission of Matters to a Vote of Security Holders

At the Annual Meeting held on March 7, 2024, the Company’s stockholders voted on eight proposals, each of which is described in more detail in the Company’s proxy statement on Schedule 14A filed with the Securities and Exchange Commission on February 8, 2024 (the “Proxy Statement”). Of the 260,257,517 shares of the Company’s common stock outstanding as of the record date, 194,030,258 shares, or approximately 74.6%, were present or represented by proxy at the Annual Meeting.

The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each such matter.

Proposal 1. Stockholders elected each of the following nominees to serve as Class II directors on the Company’s Board of Directors (the “Board”) until the Company’s 2027 Annual Meeting of Stockholders or until his or her successor has been duly elected and qualified. The voting results for such nominees were as follows:

Director Name		Votes For				Votes Withheld				Broker Non- Votes
Gerd Auffarth, M.D.			122,406,604				7,573,738				64,049,916
Julia A. Haller, M.D.			126,307,671				4,173,076				63,549,511
Andong Huang			128,730,972				1,749,775				63,549,511
Lawrence A. Kenyon			125,464,513				4,524,055				64,041,690

Proposal 2. Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding common stock in a private placement of shares of common stock and accompanying warrants at less than the “minimum price” under Nasdaq Listing Rule 5635. The voting results were as follows:

Votes For				Votes Against				Abstentions				Broker Non- Votes
	123,467,622				6,224,132				788,993				63,549,511

Proposal 3. Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding common stock upon the conversion of an outstanding convertible note at less than the “minimum price” under Nasdaq Listing Rule 5635, if required pursuant to the terms of the convertible note. The voting results were as follows:

Votes For				Votes Against				Abstentions				Broker Non- Votes
	123,394,516				6,301,788				784,443				63,549,511

Proposal 4. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of its common stock authorized for issuance from 425,000,000 to 1,200,000,000 shares. The voting results were as follows:

Votes For				Votes Against				Abstentions				Broker Non- Votes
	123,007,844				6,742,110				730,793				63,549,511

Proposal 5. Stockholders did not approve the amendment of the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. The voting results were as follows:

Votes For				Votes Against				Abstentions				Broker Non- Votes
	125,438,289				3,598,772				1,443,686				63,549,511

Proposal 6. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock, and a reduction in the number of authorized shares of common stock, at a ratio of 1-for-10 to 1-for-30. The voting results were as follows:

Votes For

Votes Against

Abstentions

Broker Non-
Votes

174,074,763

15,567,247

4,388,248

N/A

Proposal 7. Stockholders ratified the selection by the Audit Committee of the Board of KPMG LLP as the Company’s independent registered public accounting firm for its fiscal year ending September 30, 2024. The voting results were as follows:

Votes For

Votes Against

Abstentions

Broker Non-
Votes

188,948,425

3,717,708

1,364,124

N/A

Proposal 8. Stockholders approved a non-binding advisory vote on the compensation of the Company’s named executive officers. The voting results were as follows:

Votes For				Votes Against				Abstentions				Broker Non- Votes
	126,964,912				3,193,076				322,759				63,549,511

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
3.1		Certificate of Amendment of the Amended and Restated Certificate of Incorporation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Outlook Therapeutics, Inc.

Date: March 7, 2024	By:	/s/ Lawrence A. Kenyon
		Lawrence A. Kenyon
		Chief Financial Officer

EX-3.1 2 tm248235d1_ex3-1.htm EXHIBIT 3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF
INCORPORATION OF OUTLOOK THERAPEUTICS, INC.

Outlook Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that:

First: The name of the Company is Outlook Therapeutics, Inc. (the “Company”).

Second: The date of the filing the original Certificate of Incorporation of this Company with the Secretary of State of the State of Delaware was October 22, 2015 and the date of filing of the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware was May 18, 2016.

Third: Paragraph A of ARTICLE IV of the Company’s Amended and Restated Certificate of Incorporation be, and it hereby is, amended and restated to read in its entirety as follows:

“A. The Company is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Company is authorized to issue is one billion two hundred and ten million (1,210,000,000) shares. One billion two hundred million (1,200,000,000) shares shall be Common Stock, each having a par value of one cent ($0.01). Ten million (10,000,000) shares shall be Preferred Stock, each having a par value of one cent ($0.01).”

Fourth: The foregoing amendment was submitted to the stockholders of the Company for their approval, and was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

In Witness Whereof, Outlook Therapeutics, Inc. has caused this Certificate of Amendment to be signed by its Chief Financial Officer, Treasurer and Secretary this 7th day of March, 2024.

	Outlook Therapeutics, Inc.


	By:	/s/ Lawrence A. Kenyon
		Lawrence A Kenyon
		Chief Financial Officer, Treasurer and Secretary

EX-101.SCH 3 otlk-20240307.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 otlk-20240307_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Series A Warrants EX-101.PRE 5 otlk-20240307_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 07, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 07, 2024
Current Fiscal Year End Date	--09-30
Entity File Number	001-37759
Entity Registrant Name	Outlook Therapeutics, Inc.
Entity Central Index Key	0001649989
Entity Tax Identification Number	38-3982704
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	485 Route 1 South
Entity Address, Address Line Two	Building F
Entity Address, Address Line Three	Suite 320
Entity Address, City or Town	Iselin
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08830
City Area Code	609
Local Phone Number	619-3990
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	OTLK
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://outlooktherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports otlk-20240307.xsd otlk-20240307_lab.xml otlk-20240307_pre.xml tm248235d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm248235d1_8k.htm": { "nsprefix": "otlk", "nsuri": "http://outlooktherapeutics.com/20240307", "dts": { "schema": { "local": [ "otlk-20240307.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "otlk-20240307_lab.xml" ] }, "presentationLink": { "local": [ "otlk-20240307_pre.xml" ] }, "inline": { "local": [ "tm248235d1_8k.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://outlooktherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm248235d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm248235d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-031908-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-031908-xbrl.zip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end XML 16 tm248235d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001649989 2024-03-07 2024-03-07 iso4217:USD shares iso4217:USD shares false --09-30 0001649989 8-K 2024-03-07 Outlook Therapeutics, Inc. DE 001-37759 38-3982704 485 Route 1 South Building F Suite 320 Iselin NJ 08830 609 619-3990 false false false false Common Stock OTLK NASDAQ false